213 related articles for article (PubMed ID: 38049961)
21. Selective suppression of excessive GluN2C expression rescues early epilepsy in a tuberous sclerosis murine model.
Lozovaya N; Gataullina S; Tsintsadze T; Tsintsadze V; Pallesi-Pocachard E; Minlebaev M; Goriounova NA; Buhler E; Watrin F; Shityakov S; Becker AJ; Bordey A; Milh M; Scavarda D; Bulteau C; Dorfmuller G; Delalande O; Represa A; Cardoso C; Dulac O; Ben-Ari Y; Burnashev N
Nat Commun; 2014 Aug; 5():4563. PubMed ID: 25081057
[TBL] [Abstract][Full Text] [Related]
22. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
23. A brain proteomic investigation of rapamycin effects in the
Wesseling H; Elgersma Y; Bahn S
Mol Autism; 2017; 8():41. PubMed ID: 28775826
[TBL] [Abstract][Full Text] [Related]
24. Effects of antiepileptic drugs in a new TSC/mTOR-dependent epilepsy mouse model.
Koene LMC; van Grondelle SE; Proietti Onori M; Wallaard I; Kooijman NHRM; van Oort A; Schreiber J; Elgersma Y
Ann Clin Transl Neurol; 2019 Jul; 6(7):1273-1291. PubMed ID: 31353861
[TBL] [Abstract][Full Text] [Related]
25. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
26. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
27. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
28. A Bama miniature pig model of monoallelic TSC1 mutation for human tuberous sclerosis complex.
Li X; Hu T; Liu J; Fang B; Geng X; Xiong Q; Zhang L; Jin Y; Liu X; Li L; Wang Y; Li R; Bai X; Yang H; Dai Y
J Genet Genomics; 2020 Dec; 47(12):735-742. PubMed ID: 33612456
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
[TBL] [Abstract][Full Text] [Related]
30. Synaptic hyperexcitability of cytomegalic pyramidal neurons contributes to epileptogenesis in tuberous sclerosis complex.
Wu X; Sosunov AA; Lado W; Teoh JJ; Ham A; Li H; Al-Dalahmah O; Gill BJA; Arancio O; Schevon CA; Frankel WN; McKhann GM; Sulzer D; Goldman JE; Tang G
Cell Rep; 2022 Jul; 40(3):111085. PubMed ID: 35858542
[TBL] [Abstract][Full Text] [Related]
31. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
32. Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor.
Dhamne SC; Modi ME; Gray A; Bonazzi S; Craig L; Bainbridge E; Lalani L; Super CE; Schaeffer S; Capre K; Lubicka D; Liang G; Burdette D; McTighe SM; Gurnani S; Vermudez SAD; Curtis D; Wilson CJ; Hameed MQ; D'Amore A; Rotenberg A; Sahin M
Ann Clin Transl Neurol; 2023 Oct; 10(10):1790-1801. PubMed ID: 37545094
[TBL] [Abstract][Full Text] [Related]
33. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
34. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.
McMahon J; Huang X; Yang J; Komatsu M; Yue Z; Qian J; Zhu X; Huang Y
J Neurosci; 2012 Nov; 32(45):15704-14. PubMed ID: 23136410
[TBL] [Abstract][Full Text] [Related]
35. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
36. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
37. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
[TBL] [Abstract][Full Text] [Related]
38. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
39. The role of TSC1 and TSC2 proteins in neuronal axons.
Karalis V; Wood D; Teaney NA; Sahin M
Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
[TBL] [Abstract][Full Text] [Related]
40. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
